Trial Profile
A Phase 2/3 Trial of FG-4592 for Treatment of Anemia in Subjects With Lower Risk Myelodysplastic Syndrome
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 01 Aug 2023
Price :
$35
*
At a glance
- Drugs Roxadustat (Primary)
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Sponsors FibroGen
- 28 Jul 2023 Primary endpoint (Percentage of Participants With a Hemoglobin (Hb) Response to FG-4592 Without Transfusion) has been met, according to an AstraZeneca media release.
- 01 May 2023 Status changed from active, no longer recruiting to completed.
- 17 Aug 2022 Planned End Date changed from 31 May 2023 to 28 Feb 2023.